Israel’s Oramed (see here previously) has reported that its ORMD-0801 oral insulin candidate successfully reduced the liver fat in its Phase 2 trial on Type 2 diabetes patients with non-alcoholic steatohepatitis (“NASH”).  There were no safety issues in the double-blind, multi-center trial.

https://www.prnewswire.com/news-releases/oramed-reports-positive-top-line-results-from-phase-2-nash-trial-with-its-ormd-0801-oral-insulin-candidate-301623054.html